The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
- PMID: 20235838
- PMCID: PMC2851487
- DOI: 10.1086/651664
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
Abstract
Acute human immunodeficiency virus type 1 (HIV-1) infection is characterized by high levels of immune activation. Immunomodulation with cyclosporine combined with antiretroviral therapy (ART) in the setting of acute and early HIV-1 infection has been reported to result in enhanced immune reconstitution. Fifty-four individuals with acute and early infection were randomized to receive ART with 4 weeks of cyclosporine versus ART alone. In 48 subjects who completed the study, there were no significant differences between treatment arms in levels of proviral DNA or CD4(+) T cell counts. Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit.
Conflict of interest statement
Conflict of interest statement: There are no conflicts of interest to declare.
Figures



Similar articles
-
Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.J Antimicrob Chemother. 2017 Mar 1;72(3):829-836. doi: 10.1093/jac/dkw462. J Antimicrob Chemother. 2017. PMID: 27999018 Clinical Trial.
-
Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.J Infect Public Health. 2018 Mar-Apr;11(2):265-269. doi: 10.1016/j.jiph.2017.08.001. Epub 2017 Aug 18. J Infect Public Health. 2018. PMID: 28826735
-
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.JAMA. 2000 Jul 12;284(2):183-9. doi: 10.1001/jama.284.2.183. JAMA. 2000. PMID: 10889591 Clinical Trial.
-
[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Enferm Infecc Microbiol Clin. 2012. PMID: 22633764 Spanish.
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
Cited by
-
HIV integrase and the swan song of the CD4 T cells?Retrovirology. 2013 Dec 9;10:149. doi: 10.1186/1742-4690-10-149. Retrovirology. 2013. PMID: 24321528 Free PMC article.
-
Elevated Methylglyoxal: An Elusive Risk Factor Responsible for Early-Onset Cardiovascular Diseases in People Living with HIV-1 Infection.Viruses. 2025 Apr 8;17(4):547. doi: 10.3390/v17040547. Viruses. 2025. PMID: 40284990 Free PMC article. Review.
-
The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections.Biology (Basel). 2020 Jul 28;9(8):192. doi: 10.3390/biology9080192. Biology (Basel). 2020. PMID: 32731331 Free PMC article. Review.
-
HIV-1 gag: an emerging target for antiretroviral therapy.Curr Top Microbiol Immunol. 2015;389:171-201. doi: 10.1007/82_2015_436. Curr Top Microbiol Immunol. 2015. PMID: 25731773 Free PMC article. Review.
-
Adjunct Therapy for CD4+ T-Cell Recovery, Inflammation and Immune Activation in People Living With HIV: A Systematic Review and Meta-Analysis.Front Immunol. 2021 Feb 17;12:632119. doi: 10.3389/fimmu.2021.632119. eCollection 2021. Front Immunol. 2021. PMID: 33679779 Free PMC article.
References
-
- Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998;128:613–20. - PubMed
-
- Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis. 2007;45:381–90. - PubMed
-
- Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999;179:527–37. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UM1 AI069501/AI/NIAID NIH HHS/United States
- AI41530/AI/NIAID NIH HHS/United States
- AI069532/AI/NIAID NIH HHS/United States
- U01 AI069532/AI/NIAID NIH HHS/United States
- AI-69501/AI/NIAID NIH HHS/United States
- AI 27665/AI/NIAID NIH HHS/United States
- U01 AI069501/AI/NIAID NIH HHS/United States
- U01 AI041534/AI/NIAID NIH HHS/United States
- AI 27661/AI/NIAID NIH HHS/United States
- UM1 AI069532/AI/NIAID NIH HHS/United States
- R24 AI106039/AI/NIAID NIH HHS/United States
- AI041534/AI/NIAID NIH HHS/United States
- M01 RR000096/RR/NCRR NIH HHS/United States
- U01 AI027661/AI/NIAID NIH HHS/United States
- AI41531/AI/NIAID NIH HHS/United States
- RR024143/RR/NCRR NIH HHS/United States
- UL1 RR024143/RR/NCRR NIH HHS/United States
- U01 AI041530/AI/NIAID NIH HHS/United States
- M01RR00096/RR/NCRR NIH HHS/United States
- U01 AI043638/AI/NIAID NIH HHS/United States
- U01 AI046370/AI/NIAID NIH HHS/United States
- AI43638/AI/NIAID NIH HHS/United States
- U01 AI041531/AI/NIAID NIH HHS/United States
- AI 46370/AI/NIAID NIH HHS/United States
- U01 AI027665/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials